LIVE: An FDA expert panel is meeting today to discuss Moderna's coronavirus vaccine, likely paving away for the 2nd authorized COVID-19 shot in the US

We are off and running for a marathon meeting expected to wrap up at 5:15 p.m.

On Tuesday, the FDA released the most detailed results yet from Moderna's late-stage study in preparation for this meeting. The agency's summary showed the two-dose vaccine to be overwhelmingly protective at preventing symptomatic COVID-19 with no major safety concerns.

All in all, it's a very similar profile to Pfizer's vaccine, which was authorized last Friday, and we compared what we know about each shot here.

It's poised to be a long but important day. The panel's recommendation on whether or not to OK Moderna's vaccine is seen as the last remaining barrier to an FDA authorization decision.

Here's the agenda for the day:

9:00 a.m. — Introductions

9:30 a.m. — FDA deputy director Doran Fink outlines emergency use authorization

10:05 a.m. — Stanford researcher Steven Goodman discusses the possible options for ongoing placebo-controlled vaccine trials, given COVID-19 shots are now being rolled out

10:45 a.m. — Moderna chief medical officer Tal Zaks and senior vice president Jacqueline Miller present the biotech's vaccine data

12:00 p.m. — Public comment

1:00 p.m. — Zaks and Miller answer questions from committee members

2:00 p.m. — FDA medical officer Rachel Zhang presents the agency's perspective on the vaccine data

3:10 p.m. — Committee discusses, ultimately votes, and adjourns